President Donald Trump signed an executive order Saturday directing the Food and Drug Administration to expedite approval processes for psychedelic drugs including ibogaine, psilocybin, and LSD for mental health treatment. The order allocates $50 million in federal funding to states developing psychedelic therapy programs.
The Oval Office ceremony featured an unusual assembly of guests, including podcaster Joe Rogan, Health Secretary Robert F. Kennedy Jr., former Navy SEAL Marcus Luttrell, and Dr. Mehmet Oz. Rogan, who has championed ibogaine research on his podcast, described texting Trump about the drug's potential.
Sounds great. Do you want FDA approval? Let's do it.
Donald Trump — NPR
The executive order targets drugs currently classified under Schedule I — the federal government's most restrictive category for substances deemed to have high abuse potential and no accepted medical use. Ibogaine, derived from a West African shrub, has gained attention among military veterans as a potential treatment for post-traumatic stress disorder and opioid addiction.
FDA Commissioner Marty Makary announced the agency will issue "national priority" vouchers for three psychedelics this week, potentially allowing approvals within weeks rather than years. This marks the first time the FDA has offered to fast-track psychedelic drugs through its review process.
Al Jazeera frames this as a bipartisan policy development with broad advocacy support, emphasizing the scientific research angle and veteran mental health crisis. Their coverage focuses on the procedural aspects and potential medical benefits rather than political implications.
NPR presents this as a public health policy story, contextualizing it within America's mental health crisis and providing scientific background on psychedelic research. They emphasize the medical legitimacy angle while noting the drugs' controversial history.
SCMP approaches this as a significant US policy shift, highlighting the contradiction between federal prohibition and growing acceptance. Their framing emphasizes the regulatory complexity and international context of psychedelic treatment availability.
CNA focuses on the administrative and regulatory mechanics of the policy change, emphasizing the international context where countries like Mexico already offer these treatments. Their coverage highlights the structured, government-led approach to drug policy reform.
Indian media frames this as a significant shift in U.S. drug policy that highlights America's evolving approach to medical innovation, particularly relevant given India's own growing pharmaceutical research sector and traditional medicine practices. The coverage emphasizes the regulatory complexity and scientific potential, positioning this as part of broader global trends in mental health treatment that could impact international pharmaceutical markets where India is a key player.
Saudi outlets present this development through a cautious lens that emphasizes the medical research aspects while carefully noting the substances remain federally banned, reflecting the kingdom's conservative approach to drug policy and social issues. The framing focuses on the administrative and scientific dimensions rather than broader social implications, aligning with Saudi Arabia's emphasis on medical innovation within strict regulatory frameworks.
Turkish media coverage emphasizes the targeted medical applications and regulatory process, framing this as part of America's broader healthcare policy evolution that Turkey watches closely given its own healthcare modernization efforts. The narrative focuses on the scientific and administrative aspects while downplaying potential social controversies, reflecting Turkey's position as a bridge between Western medical practices and more conservative regional approaches to drug policy.
Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life.
Donald Trump — Al Jazeera
The initiative addresses what the administration frames as a national mental health crisis. The executive order notes that over 14 million American adults have serious mental illness, with approximately 8 million currently on prescription medications for these conditions.
Research into psychedelics for medical use has experienced a renaissance after decades of prohibition. A 2025 study in the Journal of the American Medical Association found that a single dose of LSD could reduce anxiety and depression for months. The Department of Veterans Affairs currently participates in at least five psychedelic trials across New York, California, and Oregon.
The policy represents rare bipartisan territory in American politics. Kennedy has previously advocated for expanded access to psychedelics as alternative treatments for depression and other mental health conditions, while veteran advocacy groups have pushed for ibogaine research despite safety concerns.
During the ceremony, Trump joked about trying psychedelics himself before pivoting to a more serious tone about staying busy as his approach to mental health. The president emphasized the potential impact if the drugs prove as effective as advocates claim.
Mexico currently operates ibogaine treatment centers that attract American veterans seeking alternatives to traditional therapies. The executive order could pave the way for similar facilities to operate legally within the United States following successful clinical trials and regulatory approval.